LLY
748.4
-0.53%↓
UNH
597.1
-0.6%↓
JNJ
155.44
+1.59%↑
NVO
102.59
-2.62%↓
ABBV
171.68
+2.4%↑
LLY
748.4
-0.53%↓
UNH
597.1
-0.6%↓
JNJ
155.44
+1.59%↑
NVO
102.59
-2.62%↓
ABBV
171.68
+2.4%↑
LLY
748.4
-0.53%↓
UNH
597.1
-0.6%↓
JNJ
155.44
+1.59%↑
NVO
102.59
-2.62%↓
ABBV
171.68
+2.4%↑
LLY
748.4
-0.53%↓
UNH
597.1
-0.6%↓
JNJ
155.44
+1.59%↑
NVO
102.59
-2.62%↓
ABBV
171.68
+2.4%↑
LLY
748.4
-0.53%↓
UNH
597.1
-0.6%↓
JNJ
155.44
+1.59%↑
NVO
102.59
-2.62%↓
ABBV
171.68
+2.4%↑
24h
Current
Min
62.86
Max
63.88
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +38.72 upside |
By Trading Central
Confidence
Weak Bearish Evidence
62.75 / 64.77 Support & Resistance
Past performance is not a reliable indicator of future results.
12 Nov 2024, 19:55 UTC
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
DJ
Read
12 Nov 2024, 11:02 UTC
AstraZeneca Raises Outlook, Plans U.S. Investment -- Update
DJ
Read
12 Nov 2024, 07:37 UTC
AstraZeneca Raises Outlook on Earnings, Sales Beat
DJ
Read
10 Sept 2024, 09:29 UTC
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
DJ
Read
18 Nov 2024, 10:33 UTC
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
DJ
Read
15 Nov 2024, 13:08 UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Read
15 Nov 2024, 10:29 UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Read
12 Nov 2024, 15:30 UTC
AstraZeneca Expands U.S. Investment Plan -- 2nd Update
DJ
Read
12 Nov 2024, 13:39 UTC
AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk
DJ
Read
12 Nov 2024, 10:49 UTC
AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk
DJ
Read
12 Nov 2024, 09:52 UTC
AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Raises 2024 View
DJ
Read
12 Nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Sales at $13.1B
DJ
Read
12 Nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Core EPS at $2.04
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q EPS 91c
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Net Pft $1.43B
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Oper Pft $2.11B
DJ
Read
7 Nov 2024, 08:03 UTC
China Has Detained a Senior AstraZeneca Executive -- Update
DJ
Read
6 Nov 2024, 18:55 UTC
China Has Detained Senior AstraZeneca Executive -- WSJ
DJ
Read
1 Nov 2024, 03:00 UTC
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ
DJ
Read
31 Oct 2024, 19:48 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Read
31 Oct 2024, 14:43 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ
DJ
Read
12 Sept 2024, 17:01 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
DJ
Read
12 Sept 2024, 11:00 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
DJ
Read
10 Sept 2024, 13:08 UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
DJ
Read
9 Sept 2024, 07:56 UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 87.67 USD 38.72%
High 88 USD
Low 87 USD
Based on 6 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.
By TipRanks
Strong Buy
6 ratings
5
Buy
1
Hold
0
Sell
Based on 6 analysts giving stock ratings to AstraZeneca PLC ADR - Dist in the past 3 months.
By Trading Central
Short Term
Weak Bearish Evidence
Bearish events outweigh bullish events.
Intermediate Term
Strong Bearish Evidence
All events are bearish.
Long Term
Strong Bearish Evidence
All events are bearish.
$